Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma

Davar, D and Socinski, MA and Dacic, S and Burns, TF (2015) Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Experimental Hematology and Oncology, 4 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© 2015 Davar et al. The programmed death 1 (PD-1) receptor is expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 normally expressed by infiltrating immune cells in response to viral infection. The PD-1/PD-L1 axis is a negative inhibitory pathway that down-regulates T-cells but is also used by tumors to evade anti-tumor immunity. Antibodies targeting PD-1/PD-L1 axis are capable of restoring functional anti-tumor immunity and have demonstrated efficacy in a broad range of tumor types including non-small cell lung cancer in both squamous and adenocarcinoma histologies. Ongoing issues affecting clinical development of these agents include assessment of response, optimal duration of therapy in excellent responders, predictive biomarkers and mechanisms of resistance. In this report, we describe a patient with advanced KRAS mutant heavily pretreated pulmonary adenocarcinoma who developed an excellent response after a single-dose of nivolumab. Pre-treatment tumor was found to have moderate CD3 and PD-L1 positivity by immunohistochemical staining. Evaluation of exceptional responders and non-responders are critical to furthering our understanding of the mechanisms of action (and resistance) to these agents.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Davar, D
Socinski, MA
Dacic, Ssad7@pitt.eduSAD7
Burns, TFtfb16@pitt.eduTFB16
Centers: Other Centers, Institutes, or Units > Pittsburgh Cancer Institute
Date: 14 December 2015
Date Type: Publication
Journal or Publication Title: Experimental Hematology and Oncology
Volume: 4
Number: 1
DOI or Unique Handle: 10.1186/s40164-015-0029-7
Schools and Programs: School of Medicine > Medicine
Refereed: Yes
Date Deposited: 18 Aug 2016 19:49
Last Modified: 13 Oct 2017 23:00
URI: http://d-scholarship.pitt.edu/id/eprint/28939

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item